CURRENT STATUS OF HIV VACCINES
e four human immunode ciency virus (HIV) vaccine e cacy trials undertaken in the last 12 years have provided some insights into host immune protection (Fig.  1 ). e rst two phase III clinical trials of an HIV vaccine were initiated in 1998 by VaxGen Corp. e vaccine, a gp120 subunit immunogen mixed with alum adjuvant that generated only limited levels of neutralizing antibodies in phase I and II clinical trials, showed no e cacy either in men who have sex with men or injecting drug users (1) (2) (3) (4) . e next HIV vaccine e cacy trial, the STEP trial initiated seven years later in 2005, evaluated a vaccine that primarily stimulated T cell immunity with a recombinant adenovirus (Ad5) vector.
is immunogen induced robust T cell responses to HIV gene products found inside the viral particle, as measured by means of enzymelinked immunosorbent spot (ELISPOT) and ow cytometry assays. However, despite the high immunogenicity of this vaccine, there was no reduction in acquisition or long-term control of post-infection viremia (5) . Post hoc analyses (6) demonstrated that persons with speci c human lymphocyte antigen (HLA) types, as well as those who developed a CD8 + T cell response to certain Gag and Nef HIV epitopes, exerted immune pressure on the virus in vivo. Unfortunately, post hoc analysis demonstrated an unexpected interaction in those vaccine recipients who were both uncircumcized and immune to Ad5 before vaccination.
Uncircumcized Ad5-seropositive male recipients experienced an increased rate of HIV infection for the rst 18 months a er the immunization regimen. is e ect fortunately waned over time so that between months 18 and 36 of follow-up, the risk of acquisition among these men equaled that of placebo (5) . e mechanism of these vaccine interactions remains unde ned.
More recently, the RV144 trial of the canarypox/envelope protein prime-boost combination vaccine conducted in ailand demonstrated a 31% reduction in the frequency of acquisition of HIV infection among vaccinated heterosexual men and women in this low-incidence community as compared with the control group, who received a placebo (7) . e RV144 study was a landmark clinical trial in that it provided a proof of concept that a vaccine could prevent HIV-1 infection, although the degree of e cacy was not optimal and must be improved. e trial was initiated in mid-2003, with trial results reported in late 2009 (Fig.  1 ). e success of this vaccine in reducing HIV acquisition has provided the impetus to develop HIV challenge models in nonhuman primates that mimic key aspects of HIV acquisition in humans. Such endeavors have been problematic previously because of the large number of animals required to conduct such experiments. If such models can be developed and validated, they might provide a useful platform for de ning immune correlates for HIV vaccines designed to reduce acquisition of infection. Because of di erences between human and nonhuman primate lentiviral infections, such e diversity of the immunological approaches taken by the di erent vaccine regimens that have entered human clinical e cacy trials highlights the lack of understanding of protective immune responses. Importantly, the long lag between the conduct and analyses of these trials bodes poorly for the development of an HIV vaccine; using this approach, it could take decades to develop a globally e ective vaccine (Fig. 1) . Here, we suggest a way to link empiricism with laboratory science in order to develop a more rational and faster paced coordinated program for the development of an HIV vaccine.
DEFINING IMMUNE CORRELATES OF HIV PROTECTION
Currently, there are no biomarkers that dene a reduction in the acquisition of HIV infection. As such, no known measurements either in nonhuman primate models or human phase I/II trials of the frequency or magnitude of a speci c immunological response or series of responses a er vaccination are predictive of vaccine e cacy.
erefore, one of the major goals and challenges for the HIV vaccine eld is to develop correlates of protection against HIV in the most time-and cost-e ective way possible, hopefully minimizing the number of costly and lengthy e cacy trials. is is especially important because it is likely that improvement upon the RV144 trial will be incremental. Hence, a systematic program to link reduction in acquisition of HIV infection to an enhanced immune response to the vaccine regimen is needed. To date, the only widely accepted premise for a potentially e cacious vaccine to prevent acquisition of HIV infection is that the vaccine should include the HIV envelope (Env) protein. It also appears that a combination of viral vectors and recombinant subunit proteins may be desirable components of the vaccine. However, the underlying immunological mechanisms by which this combination vaccine regimen might reduce acquisition of HIV remains unknown.
Hypothesis-driven studies in laboratory-based research are straightforward, but their application to human clinical research is more circuitous (8) . Before the question of drug or vaccine e cacy can be answered, safety testing, validation of mechanism, and speci city issues must be addressed in preliminary studies.
ese studies themselves o en provide unexpected information that generates new hypotheses. An e cacy trial-usually a randomized controlled trial-represents the ultimate test of concept that an intervention can ameliorate disease or prevent infection.
Clinical product development typically begins with phase I studies that evaluate the safety and biological activity of a drug, vaccine, or other intervention and proceeds ultimately to phase III e cacy trials that support licensure ( Fig. 2A ). e traditional pathway of product development consists of a series of "critical path" trials conducted according to individual protocols that generate and test an explicit hypothesis regarding the clinical e cacy of the intervention.
e concept for advancing a drug or vaccine is based on an understanding of molecular and disease pathogenesis and the mechanistic basis for its action. But phase I studies are descriptive and only begin to evaluate the safety and biological activity of the product under development. Phase II clinical trial evaluation a ords an opportunity to discover less frequent side e ects of the intervention and to provide better quantitation of the agent's activity and safety in a larger and more diverse participant population. Increasingly, phase II trials are being conducted in stages: an initial stage exploring the safety and immunogenicity of the vaccine (phase IIa) and a later stage (phase IIb) in which a su ciently large trial is performed in a population at increased risk for disease in order to provide some indication of e cacy. Such phase IIb studies may supply data that can refute, support, or expand the primary hypothesis and may even generate new hypotheses, creating a loop between the IIb and IIa phases to iteratively de ne the clinically predictive biomarker end points to use in phase IIa. Furthermore, it may be possible to identify an immunological correlate of protection. In the case of an HIV-1 vaccine, this correlate could be the adaptive neutralizing antibody response, CD8 + or CD4 + T cell immunity, and/or innate immune responses. If such correlates were seen while the trial was in progress, the relevant group sizes could even be expanded to more de nitively determine the importance of the correlate and the degree and durability of protection.
e transition from a phase II to a phase III trial allows for a de nitive evaluation and a rigorous test of clinical e cacy. In the absence of a validated correlate of clinical e cacy, phase III trials remain critical to the drug or vaccine development process. Such trials are best undertaken when a signal of vaccine e cacy has already been detected in the phase IIb study.
EFFICACY SIGNALS FROM PHASE II TRIALS
e key to progress stemming from phase II trials depends on two elements. First, a positive e cacy signal (such as that in the phase IIb RV144 trial) is essential if further testing of the product in question is to proceed. Such protective responses provide a proof of concept for the vaccine candidate. Second, an e cacy signal in a phase II trial might allow the identi cation of immunological correlates of protection and a strong rationale to proceed to a denitive phase III e cacy trial. e recently licensed vaccine against human papillomavirus (HPV) adopted this approach. A phase II proof-of-concept study with an HPV16 vaccine manufactured by Merck revealed striking e cacy against acquisition of HPV16 infection that correlated with an increase in antibodies to HPV16 (9) . is observation laid the foundation for a de nitive e cacy study with a multivalent HPV vaccine that contains a mixture of capsids from multiple HPV strains.
In the selection of vaccine candidates to enter phase IIb trials for the evaluation of efcacy signals, a rational approach is to prioritize and select candidates on the basis of the hypothesis that the immune responses that they have been demonstrated to trigger will provide protection from established infection. e supporting evidence that should be required to advance a product into a phase IIb study is the validation of a robust response in previous human trials. Although success in nonhuman primate challenge studies can provide some information for prioritization, they have been minimally helpful to date in selecting optimal candidates for advanced testing in humans.
Priority should be given to the selection of vaccine candidates for e cacy trial testing if (i) the candidates test new hypotheses and therefore elicit immune responses that are substantially di erent, qualitatively or quantitatively, from previous candidates and (ii) the candidates are predicted to provide protection according to current understanding of immunopathogenesis. In e ect, phase IIb trials-in addition to providing insights into the clinical e cacy of the vaccine candidates-should also explore the di erent facets of the immune response that may confer protection. Such vaccine candidates may include those that induce neutralizing antibody responses, nonneutralizing antibodies that may interdict transmission at mucosal surfaces, innate immune responses, cell-mediated immune responses directed toward speci c viral gene products, or a unique combination of these responses. In other words, the goal of these coordinated trials would be to " ll in the immunological space. "
A key ingredient in developing such coordinated studies is the nature of the study populations and the required degree of efcacy needed to develop an immune correlate. Phase II trials should be powered to demonstrate modest but notable e ects, preferably protection from HIV acquisition that is ≥40% with a lower bound above 0%, and designed to allow for prospective and timely immunological analyses of blood and mucosal samples. Previous phase IIb trials such as the RV144 ai trial were designed to allow for retrospective immunological analyses that may extend for two years a er the completion of the trial, thus precluding rapid access to information that can be important for the design of new clinical trials that test other vaccine candidates. Moreover, the trials should be conducted in populations with a su ciently high incidence of HIV infection that additional trials or adaptations of the trial can be performed and results obtained rapidly. Future approaches to clinical trial design should take these important issues into consideration.
ADAPTIVE TRIAL DESIGN
Because immunological correlates of protection are critical to the development of an HIV vaccine and because correlates cannot be identi ed unless there is some degree of e cacy, there is great potential value in accelerating the analysis and iterative design of potentially successful vaccine candidates. Unsuccessful prototypes are best discarded sooner rather than later. Without an immune correlate, relying solely on the traditional iterative clinical trial design is not optimal for the development of an HIV vaccine. Innovative clinical trial designs may prove useful for such decision-making and for prioritization of promising vaccine candidates.
Adaptive trial designs allow modi cation of the trial in response to data acquired during the study.
ey require access to evolving clinical data earlier in the process of vaccine development and may accelerate decisions about vaccines (10, 11) . Adaptive design means that one or more decision points are built into the trial based on interim trial results. Adaptations may be divided into two major types: those governed by prespeci ed rules and those that make unplanned changes (12) . We re commend the rst type, which has ample exibility; the second type may lead to bias and reduced statistical power and may complicate interpretation of results (13) . In general, this means that close monitoring of the trial is performed, allowing an adaptation of the trial a er it has begun. is might mean stopping the trial for lack of e cacy or adapting the trial if e cacy is observed.
is adaptation could include vaccinating the placebo group for immune correlate analyses, adding a booster vaccination if vaccine e cacy appears to wane, or expanding the trial design to include a higherrisk population. Despite the advantages of adaptive designs, there are certain caveats associated with the approach. For example, decisions may sometimes be based on preliminary data that may not prove de nitive. Care must also be taken to preserve the integrity and objectivity of the trial.
Besides enabling more rapid assessment and elimination of ine ective vaccines, adaptive trial designs also may allow the de nition of immunological and virological factors that a ect HIV acquisition to be more readily de ned. If vaccine e cacy studies are performed in populations with a high incidence of HIV infection, this information can be ascertained more expeditiously, with greater certainty, and possibly with greater cost e ciency. Additionally, if multiple phase II studies can be conducted in parallel, with the capability of examining e cacy end points and immune correlates in real time, the likelihood for advancing a successful vaccine to an e cacy trial in a more rapid time frame will increase greatly (Fig. 2B) . Moreover, the ability to see common immunological ndings either with di erent vaccine regimens or the same vaccine regimen in di erent populations (such as men versus women) provides more than circumstantial evidence that such responses have an underlying biological basis.
Once compelling data supporting a speci c hypothesis-for example, that a de ned mucosal antibody response or innate immune signature is associated with reduced acquisition of HIV infection a er vaccination-have been solidi ed through phase II studies, de nitive phase III e cacy studies would be warranted. Such a strategic pathway requires a long-term view of HIV vaccine development; otherwise, there may be temptations to only test the latest attractive hypotheses in the absence of su cient data, which may or may not prove valid. Systematic evaluation of vaccine candidates as described above would be the most likely pathway leading to ultimate success.
THE RV144 TRIAL AND FUTURE HIV VACCINES
e eld now stands at a crossroads and faces two main challenges: How does one build on previous e orts and de ne parameters for moving forward, and how can the clinical development of an HIV vaccine be accelerated while the eld simultaneously addresses basic scienti c issues key to the ultimate success of the e ort? Continued vaccine-related basic research is needed to provide a better understanding of the complex mechanisms by which HIV establishes infection, evades host immune responses, and is sometimes controlled naturally. Understanding the earliest events in infection-particularly within the rst few hours to days at the portals of entry-is a particular priority. Ongoing research on the immunological correlates of protection in the RV144 trial has not yet allowed the eld to rule out or to favor any speci c cellular or humoral mechanisms of protection. Improvement on the results of the RV144 trial with other vaccine candidates may require vaccine designs that induce an integrated immune response that includes innate, cellular, and humoral immunity.
e RV144 trial has provided an important lead with regard to preventing HIV-1 infection. e question now is to determine how best to capitalize on this result and chart the most direct pathway to success. Work is ongoing to aggressively determine any observable immunological correlates of protection in the RV144 clinical trial. is task will be di cult, although hopefully not impossible, because of the small number of clinical samples available. Future clinical trials should have the resources to obtain adequate clinical samples for the real-time study of immune responses generated by the vaccine. e eld will also need to intensively investigate vaccine candidates in human e cacy trials that have attributes designed to improve on the results obtained in the RV144 trial. Such attributes might include more potent vectors for expression and immunogenicity of HIV envelope immunogens, and HIV envelope immunogens that can induce durable, broad responses of both traditional neutralizing and nonneutralizing antibodies at mucosal surfaces.
e nonhuman primate SIV infection model is likely to o er important insights into the pathogenic events at mucosal surfaces at the time of transmission. Such studies should be closely linked and coordinated with ongoing clinical trials in humans so that they contribute to the generation and testing of relevant hypotheses.
ese efforts are consistent and aligned with the approaches and philosophy articulated in the 2010 strategic plan of the HIV Global Vaccine Enterprise (14) .
CONCLUSION
e results from the HIV vaccine e cacy trials conducted in the past 12 years provide optimism that developing an e ective HIV vaccine is possible. However, a review of HIV vaccine e cacy trials has indicated that the pace of conduct of such trials is painfully slow and that acceleration of clinical vaccine research is needed. Unfortunately, neither current preclinical nonhuman primate models or even earlyphase human clinical trials provide a sound scienti c basis for developing data on what types of immune responses or signatureswhether they be humoral, adaptive, or innate-are associated with vaccine-induced protection. Such signatures require close collaboration between sophisticated laboratory investigations and human vaccine e cacy trials. Adaptive trial designs must be implemented if we are to engage in a more robust, systematic, and methodical approach to HIV vaccine development. Changing the approach to clinical translational research-from sequential human trials that take years for completion to parallel adaptive hypothesis-generating clinical trials evaluated in real time-can both inform the eld with regard to the immunological basis for the prevention of HIV infection and accelerate the path to a highly e ective HIV vaccine. 
